<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369641</url>
  </required_header>
  <id_info>
    <org_study_id>11D.99</org_study_id>
    <secondary_id>2011-03</secondary_id>
    <nct_id>NCT01369641</nct_id>
  </id_info>
  <brief_title>The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy</brief_title>
  <official_title>A Pilot, Randomized, Self-controlled Study of the Effects of Intratympanic Sodium Thiosulfate on the Degree of Hearing Loss in Patients Receiving Cisplatin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, randomized, self-controlled study of the effects of intratympanic sodium&#xD;
      thiosulfate (STS) on the degree of hearing loss in patients receiving cisplatin therapy.&#xD;
      Sodium thiosulfate is an inactive ingredient contained in sulfacetamide ophthalmic solution&#xD;
      which is used routinely as an otic solution delivered to the middle ear space.&#xD;
&#xD;
      The hypothesis of this study is that local administration of sodium thiosulfate (STS) will&#xD;
      result in improved hearing compared to ears not receiving the study drug in patients&#xD;
      receiving systemic cisplatin therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platinum-based chemotherapeutic agents are used to treat a number of malignant tumors, both&#xD;
      in children and adults. Examples of such tumors include: osteosarcoma, Wilms' tumor,&#xD;
      rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma, primary brain tumors, carcinoma, and&#xD;
      various other solid tumors. Cisplatin is associated with a dose-dependent, high frequency&#xD;
      sensorineural hearing loss. With increasing doses, the hearing loss worsens to include the&#xD;
      speech frequencies. Vestibular function can also be damaged by platinum-based toxicity.&#xD;
      Cisplatin causes ototoxicity through the formation of reactive oxygen species and activation&#xD;
      of the apoptotic pathway in outer hair cells and the stria vascularis.&#xD;
&#xD;
      Rates of ototoxicity are approximately 80% with audiologic findings of hearing loss, and 20%&#xD;
      with symptomatic hearing loss. These numbers are higher for those receiving high dose&#xD;
      cisplatin, children, those with prior irradiation and those with prior hearing loss.&#xD;
&#xD;
      A number of agents have been investigated in animal models as otoprotection against the toxic&#xD;
      effects of cis- and carboplatin. Among these, sodium thiosulfate (STS) has shown particular&#xD;
      promise as an otoprotective agent. STS is approved by the US Food and Drug Administration&#xD;
      (FDA) as an antidote for cyanide and nitroprusside toxicity and for calciphylaxis. STS has&#xD;
      been shown to act as both an antioxidant as well as a chelating agent in vivo. The chelating&#xD;
      properties of the sulfur-thiol functional group are believed to be responsible for the&#xD;
      otoprotective effects of STS, binding to, and inactivating the platinum. The thiol compound&#xD;
      may also act to scavenge reactive oxygen species produced by the platinum, thus preventing&#xD;
      the initiation of the apoptotic pathway.&#xD;
&#xD;
      Several studies have demonstrated the otoprotective effects of intravenous STS in animal&#xD;
      models. Subsequent studies have shown similar benefit when STS is administered intravenously&#xD;
      to humans. A major drawback to this mode of delivery, however, is the fear that it reduces&#xD;
      the anti-tumor activity of the platinum. Sodium thiosulfate is believed to bind to cisplatin,&#xD;
      forming a complex that is then excreted by the kidneys. Though this may decrease the&#xD;
      ototoxicity associated with the platinum, it may also decrease the anti-neoplastic properties&#xD;
      of the agent. There are conflicting reports of reduced tumoricidal properties of STS in&#xD;
      vitro, though there are no in vivo studies suggesting this adverse effect in vivo.&#xD;
&#xD;
      In view of the potential for systemic STS to reduce the tumoricidal effects of platinum&#xD;
      agents, researchers have sought an alternate mode of delivery. Recent animal studies have&#xD;
      examined the effect of sodium thiosulfate delivered locally to the middle ear space. Stocks,&#xD;
      et al demonstrated an otoprotective effect of STS delivered to the middle ear space of guinea&#xD;
      pigs. Wang, et al showed complete prevention of the ototoxic effects of cisplatin in guinea&#xD;
      pigs treated with round window application of STS. In their study, both the compound action&#xD;
      potential (CAP) and distortion product otoacoustic emissions (DPOAE) were unchanged, and both&#xD;
      outer hair cells (OHC) and inner hair cells (IHC) were preserved. This effect, however, was&#xD;
      not demonstrated in a similar study by Wimmer, et al. The temporal and spatial separation of&#xD;
      the platinum and STS in these animal studies prompted Zuur and colleagues to state that, &quot;in&#xD;
      the future, it may be desirable to examine additional possibilities for two-route&#xD;
      administration schemes for chemotherapy and otoprotective drugs in humans.&quot; There are no&#xD;
      studies to date of intratympanic sodium thiosulfate in humans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual&#xD;
  </why_stopped>
  <start_date type="Actual">August 24, 2011</start_date>
  <completion_date type="Actual">May 2, 2013</completion_date>
  <primary_completion_date type="Actual">March 10, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Intratympanic Sodium Thiosulfate (STS)</measure>
    <time_frame>Through 1 year post-treatment</time_frame>
    <description>To assess the efficacy of intratympanic sodium thiosulfate (STS) on reducing the degree or incidence of hearing loss in patients receiving systemic cisplatin therapy using puretone and speech audiometry, and distortion product otoacoustic emissions (DPOAE).&#xD;
Pure tone and speech audiometry: hearing will be assessed prior to any initiation of cisplatin therapy, again at three weeks, 6 weeks, 12 weeks, and every 6 months thereafter for up to one year.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Ear - Sodium Thiosulfate (STS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Ear - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Insertion of Pressure Equalization (PE) Tubes</intervention_name>
    <description>If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.</description>
    <arm_group_label>Comparator Ear - Placebo</arm_group_label>
    <arm_group_label>Experimental Ear - Sodium Thiosulfate (STS)</arm_group_label>
    <other_name>PE</other_name>
    <other_name>tympanostomy tubes</other_name>
    <other_name>myringotomy tubes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Thiosulfate (STS)</intervention_name>
    <description>Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.</description>
    <arm_group_label>Experimental Ear - Sodium Thiosulfate (STS)</arm_group_label>
    <other_name>sodium thiosulphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline (Placebo)</intervention_name>
    <description>Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.</description>
    <arm_group_label>Comparator Ear - Placebo</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2</description>
    <arm_group_label>Comparator Ear - Placebo</arm_group_label>
    <arm_group_label>Experimental Ear - Sodium Thiosulfate (STS)</arm_group_label>
    <other_name>cisplatinum</other_name>
    <other_name>cis-diamminedichloroplatinum(II)</other_name>
    <other_name>CDDP</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol-AQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults receiving cisplatin therapy in the dose range of 80-120mg/m2&#xD;
&#xD;
          2. Subjects are capable of giving informed consent, or if appropriate, have an acceptable&#xD;
             surrogate capable of giving consent on the subject's behalf.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with active middle ear disease (unilateral or bilateral)&#xD;
&#xD;
          2. Subjects with prior treatment with platinum-based chemotherapeutic agent or other&#xD;
             ototoxic agent&#xD;
&#xD;
          3. Subjects with an allergy to sodium thiosulfate&#xD;
&#xD;
          4. Subjects with tumors involving cranial nerve VIII&#xD;
&#xD;
          5. Subjects with preexisting absence of otoacoustic emissions (unilateral or bilateral)&#xD;
&#xD;
          6. Subjects with more than 5 dB interaural difference in puretone threshold on initial&#xD;
             audiometric screening&#xD;
&#xD;
          7. Chronic use of known ototoxic agent (e.g. furosemide, aminoglycosides, etc)&#xD;
&#xD;
          8. Subjects with a history of prior irradiation to the head and neck.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cognetti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <results_first_submitted>January 24, 2014</results_first_submitted>
  <results_first_submitted_qc>March 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 1, 2014</results_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cisplatin</keyword>
  <keyword>STS</keyword>
  <keyword>sodium thiosulfate</keyword>
  <keyword>Adults</keyword>
  <keyword>dose range of 80-120mg/m2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium thiosulfate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sodium Thiosulfate (STS) Ear &amp; Placebo Ear</title>
          <description>Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.&#xD;
Insertion of Pressure Equalization (PE) Tubes: If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.&#xD;
Sodium Thiosulfate (STS): Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.&#xD;
Cisplatin: Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sodium Thiosulfate (STS) Ear &amp; Placebo Ear</title>
          <description>Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.&#xD;
Insertion of Pressure Equalization (PE) Tubes: If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.&#xD;
Sodium Thiosulfate (STS): Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.&#xD;
Cisplatin: Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.26" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Intratympanic Sodium Thiosulfate (STS)</title>
        <description>To assess the efficacy of intratympanic sodium thiosulfate (STS) on reducing the degree or incidence of hearing loss in patients receiving systemic cisplatin therapy using puretone and speech audiometry, and distortion product otoacoustic emissions (DPOAE).&#xD;
Pure tone and speech audiometry: hearing will be assessed prior to any initiation of cisplatin therapy, again at three weeks, 6 weeks, 12 weeks, and every 6 months thereafter for up to one year.</description>
        <time_frame>Through 1 year post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Thiosulfate (STS) Ear &amp; Placebo Ear</title>
            <description>Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.&#xD;
Insertion of Pressure Equalization (PE) Tubes: If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.&#xD;
Sodium Thiosulfate (STS): Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.&#xD;
Cisplatin: Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Intratympanic Sodium Thiosulfate (STS)</title>
          <description>To assess the efficacy of intratympanic sodium thiosulfate (STS) on reducing the degree or incidence of hearing loss in patients receiving systemic cisplatin therapy using puretone and speech audiometry, and distortion product otoacoustic emissions (DPOAE).&#xD;
Pure tone and speech audiometry: hearing will be assessed prior to any initiation of cisplatin therapy, again at three weeks, 6 weeks, 12 weeks, and every 6 months thereafter for up to one year.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sodium Thiosulfate (STS) Ear &amp; Placebo Ear</title>
          <description>Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.&#xD;
Insertion of Pressure Equalization (PE) Tubes: If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.&#xD;
Sodium Thiosulfate (STS): Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.&#xD;
Cisplatin: Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ear infaction and tympanic perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated due to poor accrual, prior to subjects being analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Cognetti, MD</name_or_title>
      <organization>Thomas Jefferson University</organization>
      <phone>215-955-6670</phone>
      <email>David.Cognetti@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

